RecruitingPhase 1NCT07652047

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities

Sponsor

Corxel Pharmaceuticals

Enrollment

90 participants

Start Date

May 11, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity, Overweight

Summary

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CX11, a drug called CX11, and others for people with obesity, overweight. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.